Literature DB >> 34461273

Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains.

Masaad Saeed Almutairi1, Anne J Gonzales-Luna2, Faris S Alnezary3, Saad B Fallatah3, M Jahangir Alam4, Khurshida Begum4, Kevin W Garey5.   

Abstract

BACKGROUND: Although Clostridioides difficile surveillance often identifies emerging strains, clinical outcome evaluations are rarely performed. Ribotype (RT) 106 is a commonly isolated C. difficile strain worldwide; however, studies investigating RT 106 clinical outcomes are limited. The purpose of this study was to investigate clinical outcomes of RT 106 infections compared with two other endemic strains of varying virulence.
METHODS: This multicenter study evaluated adults hospitalized with C. difficile infection (CDI). C. difficile samples underwent PCR ribotyping and patients infected with RT 106 were compared to patients infected with a known hypervirulent strain (RT 027) and a strain associated with less virulence (RT 014-020). Electronic medical records were reviewed by blinded investigators to assess the primary outcome of poor clinical outcome (composite of initial clinical failure, discharge to a higher level of care, 90-day CDI recurrence, and CDI-contributable mortality).
RESULTS: A total of 396 patients with CDI were identified (RT 106, 32.3%; RT 027, 29.3%; RT 014-020, 38.3%). Patients infected with RT 014-020 less often experienced a poor clinical outcome (40%) compared with RT 106 (56%) and RT 027 (65%) infection (P < 0.0001). After controlling for covariates and using RT 014-020 as a comparator, patients infected with RT 106 (OR, 2.25; 95% CI, 1.36-3.73) or RT 027 (OR, 2.56; 95% CI, 1.52-4.31) had higher odds of poor clinical outcome. Using RT 027 as the comparator, only RT 014-020 was associated with lower odds of poor clinical outcome (OR, 0.42; 95% CI, 0.27-0.65).
CONCLUSION: This study demonstrated that the emergent C. difficile RT 106 was associated with increased rates of poor clinical outcomes compared to RT 014-020 and comparable poor clinical outcomes to RT 027. These findings can help to better understand the clinical significance of this and future emerging ribotypes.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Ribotype 014–020; Ribotype 027; Surveillance; Typing

Mesh:

Substances:

Year:  2021        PMID: 34461273      PMCID: PMC8678208          DOI: 10.1016/j.anaerobe.2021.102440

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  18 in total

1.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

2.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Clostridium difficile infection: historic review.

Authors:  John G Bartlett
Journal:  Anaerobe       Date:  2009-09-12       Impact factor: 3.331

4.  Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology.

Authors:  Jonathan N V Martinson; Susan Broadaway; Egan Lohman; Christina Johnson; M Jahangir Alam; Mohammed Khaleduzzaman; Kevin W Garey; Jessica Schlackman; Vincent B Young; Kavitha Santhosh; Krishna Rao; Robert H Lyons; Seth T Walk
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

5.  Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain.

Authors:  T J Carlson; D Blasingame; A J Gonzales-Luna; F Alnezary; K W Garey
Journal:  Anaerobe       Date:  2019-12-19       Impact factor: 3.331

6.  Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.

Authors:  D N Shah; S L Aitken; L F Barragan; S Bozorgui; S Goddu; M E Navarro; Y Xie; H L DuPont; K W Garey
Journal:  J Hosp Infect       Date:  2016-04-20       Impact factor: 3.926

7.  Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals.

Authors:  Shelley S Magill; Erin O'Leary; Sarah J Janelle; Deborah L Thompson; Ghinwa Dumyati; Joelle Nadle; Lucy E Wilson; Marion A Kainer; Ruth Lynfield; Samantha Greissman; Susan M Ray; Zintars Beldavs; Cindy Gross; Wendy Bamberg; Marla Sievers; Cathleen Concannon; Nicolai Buhr; Linn Warnke; Meghan Maloney; Valerie Ocampo; Janet Brooks; Tolulope Oyewumi; Shamima Sharmin; Katherine Richards; Jean Rainbow; Monika Samper; Emily B Hancock; Denise Leaptrot; Eileen Scalise; Farzana Badrun; Ruby Phelps; Jonathan R Edwards
Journal:  N Engl J Med       Date:  2018-11-01       Impact factor: 91.245

8.  Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge.

Authors:  Kelly R Reveles; Kierra M Dotson; Anne Gonzales-Luna; Dhara Surati; Bradley T Endres; M Jahangir Alam; Kevin W Garey
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

9.  Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype.

Authors:  Qianyun Lin; Nira R Pollock; Alice Banz; Aude Lantz; Hua Xu; Limei Gu; Dale N Gerding; Kevin W Garey; Anne J Gonzales-Luna; Mingwei Zhao; Linan Song; David C Duffy; Ciaran P Kelly; Xinhua Chen
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

10.  PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255.

Authors:  Anne J Gonzales-Luna; Travis J Carlson; Kierra M Dotson; Kelley Poblete; Gabriela Costa; Julie Miranda; Chris Lancaster; Seth T Walk; Shawn Tupy; Khurshida Begum; M Jahangir Alam; Kevin W Garey
Journal:  Emerg Microbes Infect       Date:  2020-02-10       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.